Skip to content

    Breast Cancer Health Center

    Font Size

    FDA Panel Opposes Avastin for Breast Cancer

    Advisory Panel Recommends That Avastin Be Dropped as a Breast Cancer Drug
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    June 29, 2011 -- An FDA panel has recommended that the drug Avastin no longer be sold as a treatment for breast cancer.

    The unanimous recommendation came after experts concluded that Avastin offers breast cancer patients no substantial benefits but at the same time carries substantial risks.

    The panel's decision does not affect other uses for which Avastin is approved, including advanced non-small-cell lung cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, and glioblastoma brain tumors.

    But if the FDA follows the panel's recommendation, it would be a setback for the treatment of advanced metastatic breast cancer.

    The panel's decision was a blow to California-based Genentech, which manufacturers Avastin, known generically as bevacizumab. The company secured fast-track approval for the drug in 2008 after early studies showed it slowed progression of a severe form of breast cancer by an average of 5.5 months.

    But later studies failed to back up those earlier findings. The FDA panel concluded that overall, Avastin does not help breast cancer patients live substantially longer or enjoy better quality of life with the disease. The drug carries significant, sometimes fatal, cardiovascular and other side effects.

    The recommendation could lead FDA Commissioner Margaret Hamburg, MD, to suspend marketing of Avastin for the treatment of breast cancer.

    "She will make a decision based on all this information," said Karen Midthun, MD, who directs FDA's Center for Biologics Evaluation and Research. "I cannot tell you at this point when the decision will be finalized and issued," Midthun said, as she ended a two-day meeting on Avastin.

    Testimony by Patients

    "I think we all wanted Avastin to succeed. These studies didn't bear out this hope," said Natalie Compagni-Portis, the panel's patient representative.

    The decision of the FDA panel followed testimony by some patients who wanted to keep Avastin on the market while Genentech continues to study the drug.

    Heraleen Broome, a breast cancer patient who credits Avastin with keeping her alive after failing chemotherapy eight years ago, said the drug should stay on the market despite the risks.

    "Just because it doesn't work on some people it doesn't mean that everyone should be deprived," Broome said on MSNBC Wednesday.

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors